All Releases
 |
Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
Mar 3, 2010
|
7.1 KB |
|
| |
RICHMOND, Calif., March 3, 2010 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business strategy at 11:00 am ET on Wednesda...
|
|
Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
Feb 3, 2010
|
21.7 KB |
|
| |
RICHMOND, Calif., Feb 03, 2010 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported fourth quarter and full year 2009 financial results and accomplishments and provided an outlook for 2010.
For the fourth quarter ended December 31, 2009, Sangamo reported a consolidated net loss of $2.4 million, or $0.05 ...
|
|
Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
Feb 1, 2010
|
7.1 KB |
|
| |
RICHMOND, Calif., Feb 01, 2010 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business strategy at 9:00 am ET on Monday, F...
|
|
Sangamo BioSciences Announces Fourth Quarter and Full Year 2009 Conference Call and Webcast
Jan 27, 2010
|
7.6 KB |
|
| |
RICHMOND, Calif., Jan 27, 2010 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its fourth quarter and full year 2009 financial results on Wednesday, February 3, 2010, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which...
|
|
Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 1 Safety Trial of SB-728-T for HIV/AIDS
Jan 19, 2010
|
12.1 KB |
|
| |
RICHMOND, Calif., Jan 19, 2010 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that preliminary data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based product, SB-728-T, for HIV/AIDS were presented on Friday, January 15, 201...
|
|
Sangamo BioSciences Advances ZFP Therapeutic(TM) Pipeline
Jan 11, 2010
|
15.7 KB |
|
| |
RICHMOND, Calif., Jan 11, 2010 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the initiation of two new clinical trials of ZFP Therapeutics, a Phase 2b study in diabetic neuropathy (DN) and a Phase 1 trial in glioblastoma, as well as the renewal of $3.0 million in funding for the Phase 2b trial by the Ju...
|
|
Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
Jan 6, 2010
|
7.1 KB |
|
| |
RICHMOND, Calif., Jan 06, 2010 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business strategy at 2:30 pm PT (5:30 pm ET)...
|
|
Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium
Dec 9, 2009
|
14.9 KB |
|
| |
RICHMOND, Calif., Dec 09, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of preliminary data from the Phase 2 clinical trial of its ZFP Therapeutic(TM) program to develop SB-509 as a treatment for amyotrophic lateral sclerosis (ALS) at a Work in Progress session at th...
|
|
Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
Nov 18, 2009
|
8.4 KB |
|
| |
RICHMOND, Calif., Nov 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based product, SB-728-T, for HIV/AIDS were inadvertently and prematurely disclosed...
|
|
Sangamo BioSciences Reports Third Quarter 2009 Financial Results
Nov 4, 2009
|
17.1 KB |
|
| |
RICHMOND, Calif., Nov 04, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported third quarter 2009 financial results and accomplishments.
For the third quarter ended September 30, 2009, Sangamo reported a consolidated net loss of $4.9 million, or $0.12 per share, compared to a consolidated n...
|
|
Sangamo BioSciences Announces Presentation at Merriman Curhan Ford's Investor Summit 2009
Nov 3, 2009
|
8.1 KB |
|
| |
RICHMOND, Calif., Nov 03, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business strategy at 2:20 pm ET on ...
|
|
Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
Oct 28, 2009
|
8.6 KB |
|
| |
RICHMOND, Calif., Oct 28, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its third quarter 2009 financial results on Wednesday, November 4, 2009, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will ...
|
|
Sangamo BioSciences Research Collaborators Awarded Grant From California Institute for Regenerative Medicine to Develop Zinc Finger Nuclease-Based Stem Cell Therapy for HIV/AIDS
Oct 28, 2009
|
11.0 KB |
|
| |
RICHMOND, Calif, Oct 28, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the California Institute for Regenerative Medicine (CIRM) has granted a $14.5 million Disease Team Research Award to develop an AIDS-related lymphoma therapy based on the application of its zinc finger nuclea...
|
|
Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting
Oct 20, 2009
|
18.0 KB |
|
| |
RICHMOND, Calif., Oct 20, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of top-line, statistically significant Phase 2 clinical data from its ZFP Therapeutic(TM) program to develop SB-509 as a treatment for diabetic neuropathy (DN) at the Society for Neuroscience Ann...
|
|
Sangamo Announces Closing of Common Stock Offering
Oct 13, 2009
|
8.2 KB |
|
| |
RICHMOND, Calif., Oct 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the closing of its previously announced public offering of 3,000,000 shares of its common stock at a price of $7.20 per share. The net proceeds to Sangamo from the sale of shares in this offering, after deducting...
|
|
Sangamo Announces Pricing of Public Offering of Common Stock
Oct 7, 2009
|
8.2 KB |
|
| |
RICHMOND, Calif., Oct 07, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the pricing of a public offering of 3,000,000 shares of its common stock. The offering is expected to close on or about October 13, 2009, subject to the satisfaction of customary closing conditions. In addition...
|
|
Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
Oct 5, 2009
|
12.3 KB |
|
| |
ST. LOUIS and RICHMOND, Calif., Oct 05, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sigma-Aldrich Corporation (Nasdaq: SIAL) and Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced a major expansion of their existing license agreement to include the exclusive rights to develop and distribute zinc finger DNA binding protein (ZFP)-mod...
|
|
Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
Oct 1, 2009
|
11.1 KB |
|
| |
RICHMOND, Calif., Oct 01, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that research led by Donald B. Kohn, M.D., Professor of Microbiology, Immunology and Molecular Genetics (MIMG) and Pediatrics, the Director of the UCLA Human Gene Medicine Program and member of the Broad Stem Cel...
|
|
Sangamo BioSciences Announces Presentation at the JMP Securities Healthcare Conference
Sep 28, 2009
|
8.1 KB |
|
| |
RICHMOND, Calif., Sept 28, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business strategy at 9:30 am ET on...
|
|
Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
Sep 23, 2009
|
14.2 KB |
|
| |
RICHMOND, Calif., Sept 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the compan...
|
|
|
